The subcortical levels (primarily limbic, thalamic, and hypothalamic) of the CNS are depressed by chlordiazepoxide and other benzodiazepines thus producing the anxiolytic, sedative, skeletal muscle relaxant and anticonvulsant effects seen. The exact mechanism of action is unknown but postulated mechanisms include: antagonism of serotonin, increased release of and/or facilitation of gamma-aminobutyric acid (GABA) activity, and diminished release or turnover of acetylcholine in the CNS. Benzodiazepine specific receptors have been located in the mammalian brain, kidney, liver, lung, and heart. In all species studied, receptors are lacking in the white matter. Clidinium bromide is an antimuscarinic with its main action to reduce GI motility and secretion similarly to atropine. Clidinium is a quaternary ammonium compound and, unlike atropine, does not cross appreciably into the CNS or the eye and should not exhibit the same extent of CNS or ocular adverse effects that atropine possesses. For further information, refer to the atropine monograph.
Chlordiazepoxide alone may be a useful adjunct to treating certain behaviors where benzodiazepines may be useful including noise phobias in dogs; inter-cat aggression and urine spraying in cats. When combined with clidinium, it may be useful symptomatic therapy for dogs with irritable bowel syndrome.
劑量數字暫停提供：VetPro 的劑量改依 DRUGAPI 藥物資料庫對外的內容，DRUGAPI 目前不提供可直接計算的劑量。下方列出 DRUGAPI 的審查結論與劑量審查引用的來源；計算機可手動輸入劑量換算。
目前沒有公開現行獸醫標示或現代 chlordiazepoxide 專屬臨床 protocol，可同時閉合犬貓產品、診斷、劑量、安全分母、監測與停藥方式。歷史及實驗數值一律不可執行。
依出現頻率分組；嚴重副作用獨立列出，臨床上需立即辨識。
renal